Celgene Corporation
|
 | ||||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
 |
return to message board, top of board |
Re: PharmaTimes.com 5Jun2012 Article "Eyebrows raised at ASCO over Abraxane vs paclitaxe study" (150 mg dose in study never used in practice)The financial proxy for Abraxane, CELGZ, has so far been unfazed by the Rugo presentation. So there must be good reason for the "raised eyebrows" over the 150 mg dosing. Apparently the dose for the lxempra therapy was not the recommended standard either! Does Rugo have some reason for bias toward paclitaxel? http://www.onclive.com/conference-coverage/asco-2012/Two-Newer-Breast-Cancer-Therapies-Not-Superior-to-Standard-Paclitaxel-Study-Suggests
|
|||||||||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 169772 | Re: PharmaTimes.com 5Jun2012 Article "Eyebrows raised at ASCO over Abraxane vs paclitaxe study" (150 mg dose in study never used in practice) | kokope11i_om | 1 | 6/5/2012 11:21:21 PM |
| 169774 | Re: PharmaTimes.com 5Jun2012 Article "Eyebrows raised at ASCO over Abraxane vs paclitaxe study" (150 mg dose in study never used in practice) | Deadeyegame | 6/5/2012 11:31:07 PM | |
